Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04866745
Other study ID # magneto-gifto
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 10, 2021
Est. completion date July 25, 2023

Study information

Verified date May 2021
Source University of Castilla-La Mancha
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The high prevalence of knee osteoarthritis and the absence of well-defined protocols for the application of Magnetotherapy (MT), makes it necessary to investigate the effect of this therapy on patients with knee osteoarthritis. Furthermore, no studies are comparing the effectiveness of the two interventions proposed in this project (MT) and microwaves (MW), which are routinely applied in clinical practice, without solid scientific evidence to justify their use. The purpose of the present clinical trial is to compare MT with MW both combined with a therapeutic exercise program in patients with painful knee osteoarthritis and its influence on pain and function.


Description:

This study is a double-blinded, sham-controlled, randomized clinical trial whose main objective is to investigate the effect on pain and function in people with moderate knee osteoarthritis of the intervention with Magnetotherapy (MT) combined with an exercise program compared to microwave (MW) application combined with an exercise program and to MT placebo combined with an exercise program. The study will take place at several centers of primary healthcare centers in Spain. After receiving the approval of the Ethics and Clinical Research Committee of Talavera de la Reina Hospital (Toledo). It is proposed to perform the study between May 2021 to May 2022. The secondary objectives are: - To investigate the effect of intervention with MT and MW plus exercise on quality of life and psychosocial factors of pain in people with osteoarthritis of the knee. - To evaluate the effect of both interventions on knee joint kinematics and range of motion and lower limb strength. - To evaluate the success of the blinding method of participants and professionals. - To measure the possible adverse effects of the application of MT and MW in patients with moderate osteoarthritis of the knee. The participants will be randomly assigned in three groups: - Group A: Magnetotherapy combined plus exercise program. - Group B: Sham magnetotherapy plus exercise program. - Group C: Microwaves combined plus exercise program. A minimum of 60 adults, older than 45 years old, diagnosed with osteoarthritis of the knee who meet the inclusion criteria will be recruited by voluntary admission.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date July 25, 2023
Est. primary completion date January 26, 2023
Accepts healthy volunteers No
Gender All
Age group 45 Years to 85 Years
Eligibility Inclusion Criteria: - Patients older than 45 years old - Unilateral or bilateral knee osteoarthritis. - Kellgren and Lawrence (K-L) grade II or III. - Visual analog scale (VAS) greater than 40mm. - Affectation of more than one year of evolution. - Sign and understand the informed consent form. Exclusion Criteria: - Secondary cause osteoarthritis - History of uncontrolled metabolic diseases. - Decompensated or uncontrolled pathologies - Tumor processes. - Collagenopathies and neurological diseases. - Changes in medication or invasive treatments at least 1 month prior to treatment. - Receiving physiotherapy treatment or having received it one month prior to the start of the osteoarthritis study. - Patients with alterations in thermal sensitivity. - Pacemaker - Skin alterations (recent wounds or burns). - Knee prosthesis - Thrombophlebitis

Study Design


Intervention

Device:
Magnetotherapy plus exercise
The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.
Microwave plus exercise
The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.
Sham Magnetotherapy plus exercise
The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.

Locations

Country Name City State
Spain Juan Avendaño Coy Talavera De La Reina Toledo

Sponsors (4)

Lead Sponsor Collaborator
University of Castilla-La Mancha Centro de Salud Talavera Centro y Centro de Salud La Algodonera., Clínica Radiodiagnóstico Marazuela, Empresa Helios Electromedicina S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in knee pain The knee pain perceived in motion and at rest will be measured with the standard 10 cm Visual Analog Scale (VAS). It will be expressed in mm. Being the value 0 "no pain" and the value 10 "worst pain". Change from baseline at 4 weeks, 1 month and 4 months after intervention.
Primary Change in function Physical function, pain, and stiffness will be measured with the Western Ontario and McMaster Universities Arthritis Index (WOMAC-24). It is a self-administered questionnaire consisting of 24 items divided into 3 subscales. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. Change from baseline at 4 weeks, 1 month and 4 months after intervention.
Primary Daily knee pain The daily level of knee pain will be measured before every session of treatment using a standard 10 cm Visual Analog Scale (VAS). It will be expressed in mm. The value 0 will be the best and 10 the worst functionality. Before each treatment session. 3 sessions per week (total 4 weeks)
Primary Daily level of functionality The level of functionality will be measured before every session of treatment using a standard 10 cm Visual Analog Scale (VAS). It will be expressed in mm. The value 0 will be the best and 10 the worst functionality. Before each treatment session (during 4 weeks)
Primary Daily quality of sleep The quality of sleep will be measured before every session of treatment using a standard 10 cm Visual Analog Scale (VAS). It will be expressed in mm. The value 0 will be the best and 10 the worst. Before each treatment session (during 4 weeks)
Primary Daily intake of oral non-opioid analgesic medication Daily intake of oral non-opioid analgesic medication (number of pills per day) during the 24 hours interval before each treatment session being the value 0 the best and 10 the worst. Before each treatment session (during 4 weeks)
Primary Change in balance and fall risk Test timed up and go (TUG) will be expressed in seconds. It uses the time that a person takes to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down. The test will be performed 3 times. The mean of the three tests will be used. Less time performing this test indicates better mobility. Mean differences from baseline at 4 weeks, 1 month and 4 months after intervention.
Secondary Change in patient quality of life The European Quality of life 5 Dimensions (EuroQoL 5D-5L) is a questionnaire that evaluates the generic quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each health state is usually represented using a 5-digit number (profile) where 11111 indicates perfect health and 55555 the worst health state. Index change from baseline at 4 weeks, 1 month and 4 months after intervention.
Secondary Change in lower limb strength Maximal isometrical knee extension and flexion strength will be measure with a hand dynamometer and will be expressed in Kgs. The researcher will perform three measurements and the final result will be the average of the three. Mean difference from baseline at 4 weeks, 1 month and 4 months after intervention.
Secondary Blinding assesment The success of participant and assessor blinding will be evaluated through a questionnaire after each intervention with five questions: (1) "Strongly believe the applied intervention is new treatment"; (2) "Somewhat believe the applied intervention is new treatment"; (3) "Somewhat believe the applied intervention is a placebo", (4) "Strongly believe the applied intervention is a placebo", or (5) "Do not know". Post treatment at 4 weeks
Secondary Number of participants with adverse effects The number of participants who suffered adverse effects will be reported by the researcher (for example skin erythema, rush, or itching...). Post each treatment session (during 4 weeks)
Secondary Change in knee range of motion Knee active and passive range of motion will be measure with the WERIUM sensors. It will be expressed in degrees. The mean of 3 movements of flexion and extension will be calculated. Mean difference from baseline at 4 weeks, 1 month and 4 months after intervention.
Secondary Change in perceived generic health status The European Quality of life 5 Dimensions (EuroQoL 5D-5L) questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status). Change from baseline at 4 weeks, 1 month and 4 months after intervention.
Secondary Doses of analgesic and antidepressant medication The doses of analgesic and antidepressant medication will be recorded at baseline.
Taking into account the therapeutic steps of the World Health Organization and the dosage, 4 values will be established concerning the basal state: "increases, decreases, it is eliminated or it is maintained".
Change from baseline at 4 weeks.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care